Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Michael P. Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8269-854X; OpenAlex author ID A5039980118, A5122376802; NIH RePORTER profile ID 12082501. Sources: ClinicalTrials.gov.

Their work

Papers
79 (first author 2, last author 2)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
258
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 16 papers · 2020: 6 papers · 2021: 14 papers, 1 grant · 2022: 7 papers · 2023: 11 papers · 2024: 7 papers · 2025: 3 papers · 2026: 4 papers, 1 grant

Papers 50 of 79

  1. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002608↗
  2. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  3. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  4. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  5. Fatty pancreas on EUS: Risk factors, correlation with CT/MRI, and implications for pancreatic cancer screening. Co-author DOI 10.1097/eus.0000000000000109↗
  6. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  7. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  8. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  9. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00464-024-11022-3↗
  10. Retraction Note: Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarci… Co-author DOI 10.1038/s41418-024-01387-2↗
  11. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  12. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  13. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  14. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  15. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  16. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. Last author DOI 10.1007/s11605-022-05534-3↗
  17. KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Co-author DOI 10.1016/j.ccell.2023.07.002↗
  18. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
  19. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  20. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  21. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  22. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Co-author DOI 10.1101/2023.08.14.553002↗
  23. Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. Co-author DOI 10.3389/fimmu.2023.1268376↗
  24. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  25. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  26. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Co-author DOI 10.1002/jso.26989↗
  27. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  28. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  29. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Co-author DOI 10.1016/j.suronc.2021.101673↗
  30. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1248↗
  31. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci151604↗
  32. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  33. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  34. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Co-author DOI 10.1002/jso.26394↗
  35. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Co-author DOI 10.1002/jso.26650↗
  36. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  37. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  38. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Co-author DOI 10.1016/j.pan.2021.08.006↗
  39. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Co-author DOI 10.1038/s41419-021-03970-8↗
  40. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  41. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  42. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  43. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  44. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. Co-author DOI 10.1172/jci.insight.146133↗
  45. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09013-4↗
  46. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09518-y↗
  47. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  48. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Co-author DOI 10.1007/s11605-019-04126-y↗
  49. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Co-author DOI 10.1016/j.ccell.2020.04.014↗
  50. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗

Trials 1

  1. Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas Principal investigator NCT01276613↗

Grants 2

  1. Defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment R01CA269651↗
  2. Defining diverse roles of p53 in pancreatic cancer K08CA218690↗

Closest collaborators

The 25 strongest of 258 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 60 shared papers, 2015–2026 · strength 7.67
  2. Ching-Wei David Tzeng · 49 shared papers, 2017–2026 · strength 6.55
  3. Jeffrey E. Lee · 43 shared papers, 2016–2026 · strength 5.43
  4. Naruhiko Ikoma · 30 shared papers, 2020–2026 · strength 4.77
  5. Laura R. Prakash · 36 shared papers, 2016–2026 · strength 4.68
  6. Eugene Jon Koay · 28 shared papers, 2016–2025 · strength 3.27
  7. Anirban Maitra · 30 shared papers, 2017–2025 · strength 3.13
  8. Robert A. Wolff · 25 shared papers, 2016–2025 · strength 2.93
  9. Huamin Wang · 21 shared papers, 2011–2024 · strength 2.02
  10. Jason B. Fleming · 23 shared papers, 2011–2024 · strength 1.82
  11. Rebecca Anne Snyder · 8 shared papers, 2019–2026 · strength 1.77
  12. Shubham Pant · 12 shared papers, 2020–2025 · strength 1.49
  13. Ya’an Kang · 15 shared papers, 2012–2024 · strength 1.33
  14. Michael James Overman · 12 shared papers, 2016–2025 · strength 1.22
  15. Milind M. Javle · 13 shared papers, 2016–2023 · strength 1.14
  16. Timothy Eric Newhook · 7 shared papers, 2021–2026 · strength 1.14
  17. Gauri Rajani Varadhachary · 13 shared papers, 2016–2022 · strength 1.06
  18. Jean‐Nicolas Vauthey · 11 shared papers, 2016–2023 · strength 1.05
  19. Dan Zhao · 6 shared papers, 2023–2026 · strength 1.05
  20. Florencia M. McAllister · 8 shared papers, 2019–2025 · strength 0.98
  21. Hua Wang · 6 shared papers, 2021–2024 · strength 0.85
  22. David R. Fogelman · 11 shared papers, 2016–2021 · strength 0.84
  23. Haoqiang Ying · 7 shared papers, 2018–2025 · strength 0.77
  24. Pamela W. Lu · 3 shared papers, 2024–2026 · strength 0.77
  25. Robin D. Wright · 3 shared papers, 2023–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.